Alto Neuroscience Inc. (ANRO)
NYSE NYSE Primary Summary
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?
Here is how Alto Neuroscience, Inc. (ANRO) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99%
The consensus price target hints at a 62% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Alto Neuroscience Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 2,885 | $33,004 | $78,125.8 | $45,121.8 | 136.72% |
 Anthony Scaramucci SkyBridge Capital II LLC | 912,000 | $1.99M | $24.58M | $22.59M | 1,133.11% |
 Point72 Asset Management LP Point72 Asset Management LP | 503,087 | $5.67M | $13.39M | $7.72M | 136.21% |
| RWM Revisor Wealth Management LLC Revisor Wealth Management LLC | 17,130 | $385,082 | $465,079.5 | $79,997.5 | 20.77% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 11,400 | $256,272 | $315,210 | $58,938 | 23% |
Alto Neuroscience Inc. (ANRO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alto Neuroscience Inc. ever had a stock split?
Alto Neuroscience Inc. Profile
| Biotechnology Industry | Healthcare Sector | Amit Etkin CEO | NYSE Exchange | 02157Q109 CUSIP |
| US Country | 68 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the United States, founded in 2019 with its headquarters in Los Altos, California. The company is dedicated to the development of innovative treatments for major depressive disorder (MDD), post-traumatic stress disorder (PTSD), cognitive impairment associated with schizophrenia, and related conditions. Utilizing a novel approach that combines pharmacodynamically synergistic combinations and a biomarker platform for patient-specific data collection, Alto Neuroscience aims to achieve precise, personalized treatment options for psychiatric and neurological disorders.
Products and Services
-
ALTO-100
This is a flagship product currently in a phase 2b clinical trial aimed at treating patients with major depressive disorder (MDD). Another variant of ALTO-100 is undergoing a phase 2a trial for post-traumatic stress disorder (PTSD) treatment, indicating the versatility and potential broad application of the drug.
-
ALTO-300
A small molecule melatonergic agonist and serotonergic antagonist designed with antidepressant properties. It is in a phase 2b clinical trial targeting the treatment of patients suffering from MDD, showcasing the company's focused efforts in combating depressive disorders.
-
ALTO-101
A novel small molecule phosphodiesterase 4 inhibitor, currently in phase 1 clinical trials for the treatment of cognitive impairment associated with schizophrenia. This development reflects Alto Neuroscience's dedication to addressing cognitive dysfunctions related to psychiatric conditions.
-
ALTO-203
Marked as a novel small-molecule histamine H3 receptor inverse agonist, ALTO-203 is in phase 1 clinical trials to treat patients with MDD exhibiting higher levels of anhedonia. This underscores the company's innovative approach in targeting specific symptoms within broader conditions.
-
ALTO-202
An investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor, which is in a phase 1 clinical trial for the treatment of MDD. ALTO-202 represents Alto Neuroscience's commitment to exploring new pathways for treating psychiatric diseases.
-
Biomarker-Characterized Patient Identification Platform
In addition to its pharmaceutical developments, Alto Neuroscience has developed a novel pharmacodynamically synergistic combination and biomarker platform. This platform collects patient-specific data to identify biomarker-characterized patients, paving the way for personalized treatment approaches.
